^
    2d
    ReLaPSe: Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Australia and New Zealand Sarcoma Association
    New trial
    5d
    A rare case of deep fibrous histiocytoma with low-grade myxoid and dedifferentiated liposarcoma features: clinical, radiological, and histopathological insights. (PubMed, J Surg Case Rep)
    Correlation of morphology with an appropriate immunophenotype and clinical-radiologic context is essential to avoid overtreatment. Complete surgical excision is the mainstay of therapy; long-term surveillance is advisable given the deep location and size.
    Journal
    |
    CD34 (CD34 molecule)
    5d
    PROSARC-1: Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=110, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    PROSARC-2: Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. (clinicaltrials.gov)
    P2, N=40, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    Molecular and Immune Mechanisms Governing Cancer Metastasis, Including Dormancy, Microenvironmental Niches, and Tumor-Specific Programs. (PubMed, Int J Mol Sci)
    Tumor-specific metastatic programs across mesenchymal malignancies (osteosarcoma, chondrosarcoma, and liposarcoma) and selected high-burden cancers (melanoma, hepatocellular carcinoma, glioblastoma, and breast cancer) are highlighted, emphasizing shared principles and divergent organotropisms. Emerging therapeutic strategies that target both the "seed" and the "soil" are also discussed, including immunotherapy combinations, stromal/ECM normalization, chemokine-axis inhibition, epigenetic reprogramming, and liquid-biopsy-enabled minimal residual disease monitoring, to prevent reactivation and improve durable control of metastatic disease.
    Review • Journal
    |
    CTSS (Cathepsin S)
    12d
    Biallelic NF1 Inactivation and Widespread Loss of Heterozygosity in a Subset of Unclassified Fibromyxoid Mesenchymal Neoplasms. (PubMed, Genes Chromosomes Cancer)
    Two patients developed local recurrences and are alive with disease, while the remaining three had no evidence of disease. We describe an unclassified fibromyxoid mesenchymal neoplasm of uncertain malignant potential characterized by recurrent biallelic NF1 LOF and widespread genomic LOH.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • NF1 (Neurofibromin 1) • CD34 (CD34 molecule)
    12d
    A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy. (PubMed, Asia Pac J Clin Oncol)
    We separately described outcomes and treatment patterns of patients with resectable and unresectable RPS. Our findings suggest that eribulin should be considered a treatment option for unresectable RPS in clinical practice.
    Journal
    |
    CRP (C-reactive protein)
    |
    Halaven (eribulin mesylate)
    12d
    Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Imlygic (talimogene laherparepvec)
    13d
    Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity. (PubMed, Sci Transl Med)
    In summary, we identified lineage-specific defects in DDLPS, with PPARG2 as the molecular mediator of differentiation state in LPS. More broadly, our findings demonstrate how defining lineage-specific mechanisms of tumor state can inform the development of nonchemotherapeutic treatment approaches.
    Journal
    |
    IGF1 (Insulin-like growth factor 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • ARG2 (Arginase 2)
    13d
    Real-World Implementation of Next-Generation Sequencing in Sarcoma: Molecular Insights and Therapeutic Outcomes. (PubMed, Med Sci (Basel))
    Genomics-guided therapy in sarcoma is feasible and impactful. Expanding timely access to molecular profiling is essential for advancing precision oncology in the MENA region.
    Retrospective data • Journal • Real-world evidence • Next-generation sequencing • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • EWSR1 (EWS RNA Binding Protein 1) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
    |
    TP53 mutation • CDKN2A deletion • RB1 mutation
    17d
    A Case of Symptomatic Giant Retroperitoneal Intramuscular Lipoma with Clinically Suspected Well-Differentiated Liposarcoma (PubMed, Gan To Kagaku Ryoho)
    The pathological diagnosis was retroperitoneal intramuscular lipoma. One year after surgery, there is no sign of tumor recurrence.
    Journal
    |
    CDK4 (Cyclin-dependent kinase 4)
    18d
    Intratendinous Lipoma of Biceps Long Head: A Case Report and Current Concepts Review of Musculoskeletal Lipomas. (PubMed, J Orthop Case Rep)
    Intramuscular lipomas that grow to giant size can exhibit heterogeneous fat signals in MRI and need to be looked for ALTs or well-differentiated liposarcoma through histopathological examination. Staining for MDM2 homolog and cyclin-dependent kinase-4 expression that are typical for ALTs is necessary when histopathological findings are indeterminate.
    Journal
    |
    MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4)